Pharmaceutical & Life Sciences News

New Cancer Therapies Would Be Speeded by CAR-T ‘Cookbook’

Oct. 23, 2018, 10:30 AM

New cancer immunotherapy treatments using CAR-T cells could reach patients faster if academic laboratories agreed to use the same methods to create the cells, the FDA’s biologics chief said.

Novartis’s Kymriah and Kite Pharmaceuticals’ Yescarta broke open the market last year to immunotherapy, a promising new field in cancer treatment that trains a patient’s immune system to attack cancer cells. CAR-T, which stands for chimeric antigen receptor T-cell therapies, is the area of immunotherapy that has advanced the furthest in clinical development. Yescarta recorded $68 million in sales during the second quarter of 2018 for Gilead Sciences, Inc., which bought...

To read the full article log in. To learn more about a subscription click here.